By: Aaron Tallent From: oncologynewscentral.com Findings from the phase 2 ENHANCE study show that both real and sham acupuncture produced clinically meaningful improvements in perceived cognitive impairment experienced by patients with breast cancer, with real acupuncture demonstrating overall superiority. The results were presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) and strengthen evidence for a form of supportive …
New breast ultrasound approach cuts false positives by nearly a third
By: Amerigo Allegretto From: auntminnie.com A new ultrasound approach could help distinguish fluid from solid breast masses with high accuracy, according to research published December 17 in Radiology Advances. A team led by Muyinatu Bell, MD, from Johns Hopkins University in Baltimore, MD, reported that when generalized contrast-to-noise ratio was applied to short-lag spatial coherence images, doctors accurately identified masses …
Tissue Engineering Revolutionizes Breast Reconstruction
By: Alina Stoian From: yale.edu Aspects of breast reconstruction. Why it Matters Breast cancer is the most common cancer affecting women globally, with millions of new cases each year. Mastectomy, a common treatment, often leads to physical and emotional challenges for patients. Current reconstruction methods have limitations, such as complications with implants and the need for donor tissue. Tissue engineering …
Jesus looked at them and said, “With man this is impossible …
Jesus looked at them and said, “With man this is impossible, but not with God; all things are possible with God.” Mark 10:27 Barbara JacobyBarbara Jacoby is an award winning blogger that has contributed her writings to multiple online publications that have touched readers worldwide. LetLifeHappen.com
Do Inflammatory Breast Cancer Symptoms Come and Go?
From: healthline.com Symptoms of inflammatory breast cancer may fluctuate over time or become more intense, depending on this fast-growing cancer’s growth. According to the American Cancer Society, inflammatory breast cancer (IBC) accounts for roughly 1–5%Trusted Source of all breast cancer diagnoses. Unlike other noninflammatory forms of breast cancer, IBC tends to cause an entirely separate set of symptoms. In some …
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
By: Paige Britt From: targetedonc.com Key Takeaways The FDA approved T-DXd plus pertuzumab for HER2-positive metastatic breast cancer, based on DESTINY-Breast09 trial results. The combination therapy reduced disease progression or death risk by 44% compared to the standard regimen. Median progression-free survival was 40.7 months, with an overall response rate of 85.1% for T-DXd plus pertuzumab. The safety profile of …
New Antibody Halts One of the Deadliest Breast Cancers
By: Medical University of South Carolina From: scitechdaily.com Scientists have uncovered a powerful new antibody that disrupts a key protein helping triple-negative breast cancer survive and evade immunity. Triple-negative breast cancer (TNBC) is considered one of the most aggressive and difficult forms of breast cancer to treat. It grows rapidly, tends to spread at an early stage, and does not …
UCSF Study Finds a Better Way to Screen for Breast Cancer
By Elizabeth Fernandez From: ucsf.edu A pioneering study has found that an individualized approach to breast cancer screening that assesses patients’ risk, rather than automatically giving annual mammograms, can lower the chance of more advanced cancers, while still safely matching people to the amount of screening they need. The results — which come from 46,000 U.S. women enrolled in the …
Setting Future Goals for Breast Cancer Patients
View PostADCs in Breast Cancer: Shaping the Future of HER2– and TROP2-Targeted Therapy
By: Alexandra Gerlach From: pharmacytimes.com Key Takeaways ADCs target specific tumor antigens, enhancing therapeutic windows and efficacy, with HER2 and TROP-2 as key targets in breast cancer. HER2-targeting ADCs, T-DM1 and T-DXd, have shown significant benefits in early and metastatic breast cancer, improving survival and response rates. TROP-2-targeting ADCs, SG and Dato-DXd, are approved for metastatic breast cancer, showing efficacy …